<DOC>

<DOCNO>
<s docid="14BI080414_826902" num="1" wdcount="1"> 826902 </s>
</DOCNO>

<FILEID>
<s docid="14BI080414_826902" num="2" wdcount="1">14BI080414_826902</s>
</FILEID>

<HEAD>
<s docid="14BI080414_826902" num="3" wdcount="15"> Vacunación en los adultos mayores de 50 años: un desafío aún pendiente en América Latina </s>
</HEAD>

<CATEGORY>
<s docid="14BI080414_826902" num="4" wdcount="1"> Bienestar </s>
</CATEGORY>

<DATE>
<s docid="14BI080414_826902" num="5" wdcount="1"> 2014-04-08 </s>
</DATE>

<TEXT>


<s docid="14BI080414_826902" num="6" wdcount="52"> Los obstáculos y los desafíos que la vacunación en adultos mayores de 50 años presenta hoy en América latina será uno de los ejes del debate de un encuentro científico de alto nivel organizado por MSD, en el marco del Congreso Panamericano de Geriatría que tiene lugar en la ciudad de Cartagena</s>
<s docid="14BI080414_826902" num="7" wdcount="42"> En la actualidad la protección a través de la vacunación es crítica para proteger a adultos de enfermedades como la rubeola, el sarampión, la hepatitis B, la gripe, el virus papiloma humano (VPH), el tétanos, el herpes zóster y la enfermedad neumocócica</s>
<s docid="14BI080414_826902" num="8" wdcount="24"> Sin embargo, las vacunas constituyen un importante pero poco utilizado recurso para disminuir la carga de las enfermedades prevenibles por vacunas en los adultos</s>
<s docid="14BI080414_826902" num="9" wdcount="53"> Un estudio reciente publicado en la revista Annals of Internal Medicine señala que las oportunidades desaprovechadas para la vacunación en adultos son comunes, en parte porque el estado de vacunación no es evaluado en cada visita, además de que la mayoría de los médicos no informan a sus pacientes sobre las vacunas recomenadadas</s>
<s docid="14BI080414_826902" num="10" wdcount="28"> En el encuentro científico que se realiza aquí en Cartagena se hará hincapié en la importancia de optimizar la vacunación contra la enfermedad neumocócica y el herpes zóster</s>
<s docid="14BI080414_826902" num="11" wdcount="53"> La enfermedad neumocócica tiene un gran impacto sobre la salud de la población: produce cerca de 1.6 millones de muertes anuales en todo el mundo, en los países en desarrollo, la mayor parte de la carga de la enfermedad se encuentra en los adultos mayores y en los niños menores de 2 años</s>
<s docid="14BI080414_826902" num="12" wdcount="42"> Una revisión reciente realizada por parte del Instituto Sabin muestra que desde la introducción de la vacuna se observa una disminución de la enfermedad en niños y cómo la carga de la enfermedad puede estar ahora en la población de adultos mayores</s>
<s docid="14BI080414_826902" num="13" wdcount="84"> El herpes zóster, una dolorosa erupción cutánea que típicamente afecta una mitad del cuerpo o de la cara y que es conocido popularmente en algunos países de Latinoamérica como “culebrilla”, afecta a casi 1 de cada 3 personas en algún momento de su vida, pero son los adultos mayores los que presentan un mayor riesgo: la mitad de los casos ocurren en hombres y mujeres mayores de 60 años de edad, entre los que incluso las complicaciones del herpes zóster son mucho más frecuentes</s>
<s docid="14BI080414_826902" num="14" wdcount="43"> Algunos de los temas que se debatirán, dentro del programa científico del simposio son: cómo funcionan las vacunas y por qué son importantes, la vacunación en las personas mayores de 50 años, y los desafíos y oportunidades en el acceso en América latina</s>
<s docid="14BI080414_826902" num="15" wdcount="43"> Enfermedad neumocócica, avanza entre los mayores La enfermedad neumocócica (EN) es causada por Streptococcus pneumoniae, una bacteria que se encuentra en el tracto respiratorio superior de niños y adultos sanos, y que causa afecciones graves como la neumonía, la bacteriemia y la meningitis</s>
<s docid="14BI080414_826902" num="16" wdcount="16"> Aunque cualquier persona puede contraerla, quienes más riesgo tienen son las personas mayores de 65 años</s>
<s docid="14BI080414_826902" num="17" wdcount="41"> 8 En Estados Unidos, el 85% de los casos de EN se producen en adultos, en América latina una revisión epidemiológica de la situación de la enfermedad muestra que la carga de la enfermedad se ha desplazado hacia las personas mayores</s>
<s docid="14BI080414_826902" num="18" wdcount="16"> El tratamiento de la enfermedad neumocócica con antibióticos como la penicilina era más efectivo, sin embargo</s>
<s docid="14BI080414_826902" num="19" wdcount="21"> La creciente resistencia de Streptococcus pneumoniae a los antibióticos convencionales destaca la importancia de la vacunación para prevenir la enfermedad neumocócica</s>
<s docid="14BI080414_826902" num="20" wdcount="23"> Datos de Estados Unidos indican que en los adultos mayores, las tasas de mortalidad de la meningitis neumocócicas son incluso más altas (80%)</s>
<s docid="14BI080414_826902" num="21" wdcount="24"> La vacunación puede prevenir la meningitis y la bacteriemia neumocócicas y ha demostrado reducir la severidad de las neumonías neumocócicas en las personas vacunadas</s>
<s docid="14BI080414_826902" num="22" wdcount="33"> Los Centros de Control y Prevención de las Enfermedades de los Estados Unidos (CDC, por sus siglas en inglés) recomiendan que las personas mayores de 65 años reciban la vacuna antineumocócica polisacárida 23-valente</s>
<s docid="14BI080414_826902" num="23" wdcount="27"> También es recomendada para personas de 2 a 64 años con problemas de salud que requieren tratamientos prolongados y que sus organismos no son resistentes a infecciones</s>
<s docid="14BI080414_826902" num="24" wdcount="43"> La edad, un factor de riesgo de “culebrilla” El herpes zóster es una dolorosa erupción cutánea que típicamente afecta a una mitad del cuerpo o de la cara, y que es causada por el virus Varicella zoster, el mismo que ocasiona la varicela</s>
<s docid="14BI080414_826902" num="25" wdcount="23"> Cualquier persona que haya sufrido varicela puede desarrollar herpes zóster, incluso los niños, pero el riesgo de desarrollarla se incrementa con la edad</s>
<s docid="14BI080414_826902" num="26" wdcount="20"> Tal es así que la mitad de los casos ocurren en hombres y mujeres mayores de 60 años de edad</s>
<s docid="14BI080414_826902" num="27" wdcount="48"> El herpes zoster puede dar lugar a severas complicaciones como la neuralgia postherpética (un dolor intenso y debilitante en las zonas afectadas por el sarpullido), que es mucho más frecuente en las personas mayores de 60 años, en donde se concentran más de la mitad de los casos</s>
<s docid="14BI080414_826902" num="28" wdcount="80"> La vacunación está recomendada por el Comité Asesor sobre Prácticas de Inmunización para reducir el riesgo de contraer herpes zóster y el dolor que puede sobrevenir después de la enfermedad.6 El Estudio de Prevención de Herpes Zoster (Shingles Prevention Study) realizado en más de 38,000 personas mayores de 60 años demostró que el uso de la vacuna redujo en un 51.3%, el riesgo de desarrollar la enfermedad, así como también reduce en un 66,5% el riesgo de desarrollar neuralgia postherpética</s>
<s docid="14BI080414_826902" num="29" wdcount="29"> La vacuna contra el herpes zóster está aprobada para su uso en personas de 50 años y mayores y se estima que esté disponible a finales de este año.</s>


</TEXT>

</DOC>